Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
11/2008
11/27/2008WO2008142133A1 Lyophilised antigen composition
11/27/2008WO2008142124A1 Recombinant protein production in avian ebx® cells
11/27/2008WO2008141651A1 Efficient cell culture system for hepatitis c virus genotype 5a
11/27/2008WO2008141511A1 A HUMAN ANTI-TNFα MONOCLONAL ANTIBODY AND THE USE THEREOF
11/27/2008WO2008141480A1 Human angiostatin interacting and tumor metastasis involving protein variants and uses thereof
11/27/2008WO2008141449A1 Single-domain antibodies and heavy chain antibody against egfr and uses thereof
11/27/2008WO2008141438A1 Gabaergic modulators for treating airway conditions
11/27/2008WO2008141391A1 Neutralizing antibodies
11/27/2008WO2008121102A3 Hedgehog signaling pathway antagonist cancer treatment
11/27/2008WO2008118733A3 Methods of treating cancer by administering human il-18 combinations
11/27/2008WO2008113916A3 Pharmaceutical composition containing antibodies directed against the herv-w envelope
11/27/2008WO2008106115A3 Compositions and methods for determining whether a subject would benefit from co-receptor inhibitor therapy
11/27/2008WO2008105764A3 Breast milk contaminant detection device
11/27/2008WO2008103701A3 Ovr115 antibody compositions and methods of use
11/27/2008WO2008098749A3 Peptides derived from the major allergen of ragweed (ambrosia artemisiifolia) and uses thereof
11/27/2008WO2008092134A3 Tumor-specific antigens, cytotoxic t lymphocytes responsive thereto, and methods of using the same
11/27/2008WO2008091981A3 Monoclonal antibody that suppresses thyrotropin receptor constitutive activity
11/27/2008WO2008091799A3 Cell-based methods for identifying inhibitors of parkinson's disease-associated lrrk2 mutants
11/27/2008WO2008089392A3 Attenuated vaccine for tularemia
11/27/2008WO2008089022A3 Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts
11/27/2008WO2008087563A3 Lentivirus pseudotyped with influenza hemagglutinin and methods of use
11/27/2008WO2008087329A3 New drug for treating gastric cancer
11/27/2008WO2008077145A3 Treatment of il-1-beta related diseases
11/27/2008WO2008075191A3 Gas-filled microvesicles with targeting ligand in respect of fc-region of an antibody or therapeutic agent
11/27/2008WO2008070135A3 Methods of treating systemic lupus erythematosus
11/27/2008WO2008063849A3 Multiple sclerosis therapy
11/27/2008WO2008063240A3 Live bacterial vaccine
11/27/2008WO2008060381A3 Method for treating pain or opioid dependence using a specific type of non-opioid agent in combination with a selective excitatory-opioid-receptor inactivator
11/27/2008WO2008057459A3 Antagonists of pcsk9
11/27/2008WO2008057458A3 Antagonists of pcsk9
11/27/2008WO2008054532A3 Compositions and methods for treating anthrax lethality
11/27/2008WO2008032219A3 Making influenza virus vaccines without using eggs
11/27/2008WO2008032153A3 Calreticulin for its use as a medication for the treatment of cancer in a mammal
11/27/2008WO2008027739A3 Antibodies to ntb-a
11/27/2008WO2008016655A3 Method of administration of an hiv immunogenic composition
11/27/2008WO2007138339A3 Treatment of pain by use of a single chain polypeptide fusion protein
11/27/2008WO2007131129A3 Immunoglobulin associated cell-surface determinants in the treatment of b-cell disorders
11/27/2008WO2007126959A3 Methods and compositions for inducing an immune response to hiv and models for testing
11/27/2008WO2007126847A3 Coadministration of alpha-fetoprotein and a disease modifying anti-rheumatic drug for treating inflammatory arthritic disease
11/27/2008WO2007124133A3 Methods and compositions based on shiga toxin type 1 protein
11/27/2008WO2007100875A3 Nac-i as a prognostic marker and a target for therapeutic target in human cancer
11/27/2008WO2007098326A3 Method for screening hiv drug sensitivity
11/27/2008WO2007095337A3 Antibody formulation
11/27/2008WO2007095055A3 Methods and compositions for detecting viral nucleic acid in a cell
11/27/2008WO2007087453A3 Compositions and methods for treating haematological proliferative disorders
11/27/2008WO2004092209A9 S. pneumoniae antigens
11/27/2008US20080294116 Coatable Compositions, Coatings Derived Therefrom and Microarrays Having Such Coatings
11/27/2008US20080293921 HSG (histamine-succinyl-glycine)-binding antibody; binds to a targeted cancer tissue
11/27/2008US20080293660 Chemically-defined non-polymeric valency platform molecules and conjugates thereof
11/27/2008US20080293123 Compositions comprising viruses and methods for concentrating virus preparations
11/27/2008US20080293103 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
11/27/2008US20080293080 Active immunization using a siderophore receptor protein
11/27/2008US20080292704 Methods and Compositions Involving Polymeric Immunoglobulin Fusion Proteins
11/27/2008US20080292686 Vaccine
11/27/2008US20080292663 Adjuvant compositions and methods for delivering vaccines
11/27/2008US20080292662 Vaccine Comprising Recombinant Clpp Protein of Streptococcus Pneumoniae
11/27/2008US20080292661 Use of Botulinum Toxin for the Preparation of a Medicament for the Treatment of Lithiasis of Salivary Gland, Gall Bladder, Kidney, or Pancreas
11/27/2008US20080292660 Hexavalent Bovine Rotavirus Reassortant Composition Designed for Use in Developing Countries
11/27/2008US20080292659 vaccination with a live equine influenza vaccine (prime) is followed by vaccination with an inactivated influenza vaccine (boost), wherein the two shots are given no longer than 8 weeks apart; horses
11/27/2008US20080292658 Defective Influenza Virus Particles
11/27/2008US20080292657 Primate t-lymphotropic viruses
11/27/2008US20080292656 Combination of a Bacterial Cell and a Biologically Active Agent
11/27/2008US20080292655 Enhancement of the immune response for vaccine and gene therapy applications
11/27/2008US20080292654 Human Bocavirus and Methods of Diagnosis and Treatment
11/27/2008US20080292653 Live attenuated antigenically marked classical swine fever virus
11/27/2008US20080292652 Virus-Like Particles Comprising a Fusion Protein of the Coat Protein of Ap205 and an Antigenic Polypeptide
11/27/2008US20080292650 Therapeutic and diagnostic peptides
11/27/2008US20080292649 Composition for improving membrane composition and functioning of cells
11/27/2008US20080292648 Synthetic agonists of tlr9
11/27/2008US20080292647 immunogenic protein in a biodrug, was encoded from an isolated host cell transfected with the recombinant expression vector; anticarcinogenic agent for treating skin cancer; vaccine for prevention and treatment; immunotherapy
11/27/2008US20080292646 Recombinant fusion protein and polynucleotide construct for immunotoxin production
11/27/2008US20080292645 Antibody or Antibody Fragment Coupled with an Immunogenic Agent
11/27/2008US20080292644 Compositions and methods for identifying response targets and treating flavivirus infection responses
11/27/2008US20080292643 Leukocyte inactivation module
11/27/2008US20080292642 Crystalline anti-human IL-12 antibodies
11/27/2008US20080292641 Antigenic GM-CSF peptides and antibodies to GM-CSF
11/27/2008US20080292640 Methods for the treatment of il-1beta related diseases
11/27/2008US20080292639 Humanized Anti-Amyloid Antibody
11/27/2008US20080292638 monoclonal antibodies or antigen-binding fragments, that neutralize mature human transforming growth factors, useful for treating cell proliferative disorders in mammals
11/27/2008US20080292637 Therapeutic Uses of A3 Adenosine Receptor Antibodies
11/27/2008US20080292636 Chemokine panec-2 polynuleotides, polypeptides, antibodies and methods of making and using them
11/27/2008US20080292635 Allergenic latex protein
11/27/2008US20080292634 Nontypable Haemophilus Infuenzae Virulence Factors
11/27/2008US20080292633 Compositions and methods for the therapy and diagnosis of lung cancer
11/27/2008US20080292632 Irta2 Antibodies and Methods of Use
11/27/2008US20080292631 Treatment with anti-vegf antibodies
11/27/2008US20080292630 Treatment with anti-vegf antibodies
11/27/2008US20080292629 System Clock Generation Circuit
11/27/2008US20080292628 Chimeric Protein
11/27/2008US20080292627 Compositions and Methods for Treating Mood and Anxiety Disorders
11/27/2008US20080292626 Kinesin inhibitors
11/27/2008US20080292625 Prevention and treatment of cerebral amyloid angiopathy
11/27/2008US20080292624 Method of detecting and treating tuberous sclerosis complex associated disorders
11/27/2008US20080292623 Mammalian cell membrane proteins; related reagents
11/27/2008US20080292622 Methods of evaluating patients
11/27/2008US20080292621 Optimized Fc Variants and Methods for Their Generation
11/27/2008US20080292620 PRLR-Specific Antibody and Uses Thereof
11/27/2008US20080292619 Pharmaceutical Composition Containing Meltrin Antagonist
11/27/2008US20080292618 Intranuclear protein transduction through a nucleoside salvage pathway
11/27/2008US20080292617 Antibody against a peptide derived from human mutant lamin a protein and uses thereof
1 ... 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 ... 1823